Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases
PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel digital biomarkers for the self-assessment of patients suffering from generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.
gMG and NMOSD are chronic severe diseases in which progression is complex and critical to monitor. The course of NMOSD is driven by episodes of severe, sequential relapses leading to the accrual of permanent disability, while gMG is characterized by a heterogeneous collection of symptoms (including fatigue and muscle group weakness) which fluctuate over time.
Currently, no objective measurement tools exist to allow gMG and NMOSD patients to track their symptoms over time. Digital biomarkers are patient-generated physiological and behavioral measures that are collected from digital devices like smartphones and processed by algorithms. If clinically validated, these measures could provide data to improve the remote monitoring of disease symptoms.
"We believe that empowering patients through real-time digital data sharing could strengthen communication between patients and healthcare professionals, and may enable more informed disease management decisions," said Dr. Guido Sabatella, Global Medical Lead in Neurology at Alexion.
"Easy-to-use digital tools have the potential to generate reliable and objective data to better understand the real impact of the disease on patients' lives and also have the potential to demonstrate the benefits of novel therapies to keep disease under control," explains Matthieu Lamy, Ad Scientiam's President.
Scoping phases have been conducted for both programs to identify clinically meaningful digital biomarkers to monitor patients living with NMOSD or gMG. Ongoing research will inform the development of a digital medical device intended to be used by patients as a self-assessment tool.
"International, multicenter, comparative studies against clinical gold standards, such as the Quantitative Myasthenia Gravis score and assessments of visual function, ambulation and dexterity in NMOSD, will be deployed to confirm the clinical relevance of selected digital biomarkers," according to Dr. Saad Zinaï, Ad Scientiam's Chief Medical Officer.
About Ad Scientiam
We strongly believe that continuously monitoring the progression of severe and disabling diseases in real life is crucial for delivering better care.
To achieve this, we create and clinically validate digital biomarkers that make visible these previously undetectable changes. These biomarkers are developed using data collected through smartphones and transformed using proprietary algorithms.
Hospital institutions such as the Paris Brain Institute (ICM) and pharmaceutical companies, including Biogen, Janssen, Roche, Pfizer, Vertex, and Novartis, trust us. In 2019, we launched MSCopilot®, the first CE-marked software medical device for the self-assessment of patients with multiple sclerosis. We are currently validating new devices in neuroscience, rare diseases, and mental disorders. Ad Scientiam is ISO 13485 certified.
Check our LinkedIn and Facebook page, or visit adscientiam.com.
Press contact: info@adscientiam.com
Contact Information:
Saad Zinaï
Chief Medical Officer
szinai@adscientiam.com
+33768008666
Matthieu Lamy
President
mlamy@adscientiam.com
+33768008666
Related Files
FEB2023_Ad Scientiam digital biomarkers PR_Final_for Newswire.pdf
Related Images
To view this piece of content from cdn.newswire.com, please give your consent at the top of this page.
Image 1: Ad Scientiam Logo
This content was issued through the press release distribution service at Newswire.com.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Offentliggørelse af ajourført prospekt for afdeling I&T Nordiske Aktier Large Cap8.12.2023 17:15:00 CET | pressemeddelelse
Afdelingens prospekt er gennemgået og opdateret som en del af den årlige ajourføring, herunder med opdateringer af risikofaktorer for de enkelte afdelinger. Herudover er prospektet ajourført med regnskabstal og satser iht. regnskabet for 2022. Afsnittet om ÅOP er slettet, idet disse oplysninger ikke længere skal fremgå af et prospekt. Afslutningsvist er der foretaget redaktionelle ændringer. Eventuel henvendelse vedrørende denne meddelelse kan rettes til adm. direktør Erling Skorstad, tlf. 44 55 86 50. Med venlig hilsen Investeringsforeningen Investin Erling Skorstad Adm. direktør Vedhæftet fil Prospekt_Investin_IT_Nordiske_Aktier_Large_Cap_081223_final_RTS
Rapala VMC Corporation: Strong Team to Implement New 2024-2026 Global Strategy8.12.2023 17:01:00 CET | Press release
Press Release To accelerate its transformation process, Rapala VMC Corporation has today announced its new Global Management Team. The new management team, together with several other key managers all over the world, will focus on implementing the new strategic plan for 2024-26. An important part of the implementation process are clear and measurable projects that focus on improving profitability and working capital management. Rapala believes the normalization of the over-demand situation created by the coronavirusis nearing completion and believes the normalization of the market will benefit Rapala. The company is closely monitoring market trends and expects that the recovery will open up opportunities for new growth plans. Rapala's success is based not only on strong globally renowned brands, but also on skilled, professional and committed personnel. The company continuously invests in the development of its personnel and the improvement of working conditions to ensure a high level
Rapala VMC Corporation: Changes in Global Management Team8.12.2023 17:00:00 CET | Press release
Rapala VMC Corporation, Changes board/management/auditors, December 8, 2023 at 06:00 p.m. EET Jean-Philippe Nicolle, who is already a member of the Global Management Team and currently the Chief Financial Officer, has been appointed as Chief Operating Officer responsible for Business Performance, Finance Controlling and Internal Auditing as of January 1, 2024. Miikka Tarna has been appointed as a member of Global Management Team and Chief Financial Officer as of January 1, 2024. Tarna has worked for the Rapala VMC Group since 2010 and is currently Deputy Chief Financial Officer. Tuomas Akkanen has been appointed as a member of Global Management Team and Executive Vice President, Head of Group Supply Chain and Winter Sports as of January 1, 2024. Akkanen has worked for the Rapala VMC Group since 2017 and is currently head of Group Supply Chain and Winter Sports. Päivi Ohvo has been appointed as a member of Global Management Team and Executive Vice President, Human Resources, as of Janua
Switch auction results: Housing Financing Fund bond series HFF150644 and HFF1504348.12.2023 16:50:00 CET | Press release
Today HF Fund concluded two switch auctions in which owners of HFF150644 were invited to exchange the bonds for indexed RIKS 33 0321 Treasury bonds and owners of HFF150434 were invited to exchange the bonds for indexed RIKS 30 0701 Treasury bonds. Bids in the nominal amount of 11,069,000,000 were submitted for RIKS 33 0321, and bids in the nominal amount of 11,069,000,000 were accepted at a predetermined price of 102.150. In exchange, HF Fund will buy back HFF150644 bonds in the nominal amount of 9,798,017,270 at a predetermined price of 100.00. Bids in the nominal amount of 16,651,000,000 were submitted for RIKS 30 0701, and bids in the nominal amount of 12,150,000,000 were accepted at a predetermined price of 102.400. In exchange, HF Fund will buy back HFF150434 bonds in the nominal amount of 16,287,685,500 at a predetermined price of 100.00. Due to strong demand HF-Fund is considering a similar future offerings that will be announced in due course. Further information can be obtaine
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS8.12.2023 16:20:00 CET | Press release
Bid procedure, 2023-12-15BondsSWEDISH GOVERNMENT: 1061. SE0011281922. 2029-11-12 SWEDISH GOVERNMENT: 1062, SE0013935319, 2031-05-12 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 Bid date2023-12-15Bid times09.00-10.00 (CET/CEST) on the Bid dateOffered volume (corresponding nominal amount)1061: 700 million SEK +/-700 million SEK 1062: 700 million SEK +/-700 million SEK 1053: 700 million SEK +/-700 million SEK Highest permitted bid volume (corresponding nominal amount)1061: 700 million SEK per bid 1062: 700 million SEK per bid 1053: 700 million SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 10 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2023-12-19Settlement amountTo be paid to the Riksbank's account in Euroclear Sweden AB's securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK Stockholm, 2023-12-08 This is a translation of the special